Research Technician Associate

Yulia Manenkova, MS, MA

858-***-****

*****.*********@*****.***

Summary

Biologist with 12+ years research experience in biotechnology, pharmaceutical and cosmetic industries. Possesses broad research experience in in vivo and in vitro pharmacology for immunology and oncology. Motivated team player.

Education

M.A. Biology (1999) University of California, Santa Barbara, EEMB, Program in Pharmacology

M.S. Chemistry (1990) Lomonosov Moscow State University, Chemistry Department

Employment

Research Associate, Pimera Inc. (October 2015 – June 2017)

- Screened a library of novel proprietary anti-cancer therapeutics, testing their effects on target inhibition and cell viability

- Performed extensive characterization of Pimera's lead compound, PMR-116 by delineating its mechanism of action, assessing pharmacological properties and performing drug combination studies

- Played crucial role in the execution of SoW for CDMRP Breakthrough Award (Level 2) "Targeting Breast Cancer Metastasis through Selective Inhibition of RNA Polymerase I" leading to the successful filing of yearly report

Professional Research Biologist, SkinMedica, an Allergan Company

(August 2013 - December 2014)

- Played essential role in establishing and managing fully functional skin biology laboratory

- Tested SkinMedica proprietary cosmetic formulations using human skin model for anti-ageing benefits and skin-lightening properties.

- Provided extensive data on the effect of TNS essential serum on gene expression the effect of Lytera on inhibition of lipid peroxidation to the Marketing Team.

Research Technician II, La Jolla Institute for Allergy and Immunology

(June 2008 - August 2013)

- Validated combinations therapies of oral insulin with anti-CD3 and anti-CD3 with GAD65 for the treatment of autoimmune diabetes in mouse models.

- Conducted research into antigen-specific induction of regulatory T cells for the treatment of Type 1 diabetes.

- Performed extensive research in the role of OX-40 agonist in the antigen-specific prevention of type 1 diabetes in NOD mice

• Research Associate II, Diazyme Laboratories, Division of General Atomics (June 2004 - June 2008)

- Collected extensive in vivo and in vitro data on the effect of a small molecule inhibitor of DNA transmethylation on CD4 T-Cell activation and amelioration of the symptoms of Multiple Sclerosis and Lupus in mouse models

- Developed proprietary Diazyme enzyme assays for the diagnosis of cardiovascular disease for automated chemistry analyzers

Skills

•Cell culture, cell isolation and purification, cell-based assays

•Flow Cytometry (LSRII, FACSCalibur)

•Immuno-histochemistry

•Immunofluorescent staining

•ELISA, ELISPOT

•DNA, RNA isolation

•PCR, qPCR

•Western blot

Publications

Preexisting Autoantibodies Predict Efficacy of Oral Insulin to Cure Autoimmune Diabetes in Combination with anti-CD3. Alusha A. Mamchak, Yulia Manenkova, Wilhem Leconet, Yanan Zheng, Jason R. Chan, Cynthia L. Stokes, Lisl K.M. Shoda, Matthias von Herrath, and Damien Bresson. Diabetes (2012).

Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment. Damien Bresson, Georgia Fousteri, Yulia Manenkova, Michael Croft, Matthias von Herrath. Journal of Autoimmunity, 37, (2011) 342- 351

Genetic-induced Variations in the GAD65 T-cell Repertoire Governs Efficacy of Anti-CD3/GAD65 Combination Therapy in New-onset Type 1 Diabetes. Damien Bresson, Matthew Fradkin, Yulia Manenkova, Diane Rottembourg and Matthias von Herrath. Molecular Therapy (2010) 18 2, 307-316

Inhibition of Transmethylation Down-Regulates CD4 T Cell Activation and Curtails Development of Autoimmunity in a Model System. Brian R. Lawson, Yulia Manenkova, Jasimuddin Ahamed, Xiaoru Chan, Jian-Ping Zou, Roberto Baccala, Argyrious N. Theofilopoulus and Chong Yuan. The Journal of Immunology, (2007) 178: 5366-5374

References:

Matthias Von Herrath, MD, Professor, La Jolla Institute for Immunology: ********@***.***

Denis Drygin, PhD, Vice President, Pimera : *******@******.***; 760-***-****

James Pavlovich, PhD, Scientist, Apeel Sciences: *****.*********@*************.***; 805-***-****

Contact this candidate